A breakthrough in cardiovascular prevention shows a widely used diabetes medication could dramatically reduce heart failure risk in a specific high-risk genetic group. Researchers from Harvard Medical School, Mass General Brigham, and MIT analyzed data from over 12,000 adults in the DECLARE-TIMI 58 trial. The study, published in Nature Medicine, focused on SGLT2 inhibitor dapagliflozin and its impact on patients carrying inherited variants for cardiomyopathy, a progressive heart muscle disease.
After a median follow-up of 4.2 years, the drug lowered heart failure hospitalizations significantly more in genetic carriers than in non-carriers. Among carriers with no prior heart failure history, 12.8 percent in the placebo group developed the condition. Zero events were recorded in the group treated with dapagliflozin. The protective effect was approximately eight times stronger in those with the genetic variant.
Historically, identifying these genetic markers meant delivering a high-risk diagnosis with few targeted preventive options. Today, clinicians have a proven tool. Co-lead author Dr. Shinwan Kany emphasized that these findings transform genetic screening from a passive warning into an actionable prevention strategy. Independent cardiologist Dr. Andrew Freeman called the research important and provocative, signaling a shift toward genetically informed precision medicine.
While SGLT2 inhibitors are already foundational treatments for heart failure and chronic kidney disease, this analysis highlights their potential for early intervention in genetically predisposed patients. Experts caution that the study represents a hypothesis-generating analysis with a narrow sample size. Further clinical trials are required to validate these results before changing standard practice.
Preventive cardiology could soon incorporate routine genetic screening to identify high-risk individuals years before symptoms like shortness of breath or fluid retention appear. Physicians advise patients with personal or family histories of cardiovascular events to discuss these options with their healthcare providers. As therapeutic precision advances, targeted prevention may redefine cardiovascular care for at-risk populations.